On Thursday November 9, at 09:00 CET, Devyser Diagnostics AB will host an online presentation of its Q3 2023 report (which will have been published earlier on November 9, at 07.30 CET).…
Devyser and Thermo Fisher Scientific have entered into a collaboration agreement to promote laboratory services. The goal is to partner with pharmaceutical companies to support their…
Devyser and Thermo Fisher Scientific have agreed to expand commercial collaboration by including Brazil in the exclusive collaboration and distribution agreement for Devyser's…
“The second quarter of the year saw an improvement in EBIT compared with recent quarters, continued high gross margins, strong growth and an exclusive collaboration and distribution…
On Wednesday August 23, at 09:00 CET, Devyser Diagnostics AB will host an online presentation of its Q2 2023 report (which will have been published earlier on August 23, at 07.30 CET).…
Devyser's novel test for detecting donor-derived cell-free DNA in blood samples from kidney-transplant patients and its product for screening and follow-up of stem cell transplanted…
Devyser has inaugurated its CLIA-certified laboratory in Atlanta, Georgia. The laboratory will offer clinical test services for hereditary diseases, oncology, and post-transplant…
Devyser is thrilled to announce the launch of two new products, Devyser LynchFAP and Devyser BRCA PALB2. These kits offer efficient, targeted, and confident analysis of genes associated…
Devyser's Deputy CEO and founder Ulf Klangby will leave his position within the company for an advisory role as a consultant as of July 1, 2023.
Ulf Klangby will leave his operational…
Devyser is today announcing that its product for non-invasive fetal RHD testing has been granted regulatory approval in Canada. Devyser already has a contract with Canada’s Héma-Québec to…
